<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=MacroGenics%2C_Inc.</id>
	<title>MacroGenics, Inc. - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=MacroGenics%2C_Inc."/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=MacroGenics,_Inc.&amp;action=history"/>
	<updated>2026-04-06T00:38:04Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=MacroGenics,_Inc.&amp;diff=430215&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei MacroGenics, Inc. listata cu simbolul US.MGNX  ==Descriere companie== MacroGenics, Inc. (https://www.macrogenics.com/) is a biopharmaceutical company. The Company is focused on developing and commercializing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company's lead product, MARGENZA, is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adul...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=MacroGenics,_Inc.&amp;diff=430215&amp;oldid=prev"/>
		<updated>2024-09-18T18:12:26Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei MacroGenics, Inc. listata cu simbolul US.MGNX  ==Descriere companie== MacroGenics, Inc. (https://www.macrogenics.com/) is a biopharmaceutical company. The Company is focused on developing and commercializing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company&amp;#039;s lead product, MARGENZA, is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adul...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei MacroGenics, Inc. listata cu simbolul US.MGNX&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
MacroGenics, Inc. (https://www.macrogenics.com/) is a biopharmaceutical company. The Company is focused on developing and commercializing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company's lead product, MARGENZA, is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. In addition, the Company has a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, such as Flotetuzumab (CD123 x CD3), Retifanlimab (PD-1), Enoblituzumab (anti-B7-H3), Tebotelimab (PD-1 x LAG-3), MGD019 (PD-1 x CTLA-4), MGC018 (B7-H3), IMGC936 (ADAM9) and MGD014 (HIV x CD3). These pipelines are created primarily using its antibody-based technology platforms.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.MGNX&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre MacroGenics, Inc. (US.MGNX)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.MGNX&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.MGNX]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>